{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T19:50:51Z","timestamp":1791661851779,"version":"4.3.4"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ijgc.2026.105601","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T15:42:26Z","timestamp":1790178146000},"page":"105601","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Early experience with mirvetuximab soravtansine in the treatment of recurrent low- grade serous ovarian carcinoma"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-0475-3880","authenticated-orcid":false,"given":"Elio","family":"Tahan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0850-7853","authenticated-orcid":false,"given":"Charlotte C.","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aradhana M.","family":"Venkatesan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren P.","family":"Cobb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil K.","family":"Sood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Travis T.","family":"Sims","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1267-4371","authenticated-orcid":false,"given":"Jolyn S.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1922-0156","authenticated-orcid":false,"given":"Shannon N.","family":"Westin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7691-9123","authenticated-orcid":false,"given":"Shrina","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9712-2140","authenticated-orcid":false,"given":"David M.","family":"Gershenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijgc.2026.105601_bib1","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1274088","article-title":"A comprehensive overview on antibody-drug conjugates: from the conceptualization to cancer therapy","volume":"14","author":"Riccardi","year":"2023","journal-title":"Front Pharmacol"},{"issue":"1","key":"10.1016\/j.ijgc.2026.105601_bib2","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","article-title":"Antibody drug conjugate: the \u201cbiological missile\u201d for targeted cancer therapy","volume":"7","author":"Fu","year":"2022","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"10.1016\/j.ijgc.2026.105601_bib3","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s13045-025-01686-2","article-title":"Mirvetuximab soravtansine: current and future applications","volume":"18","author":"Kong","year":"2025","journal-title":"J Hematol Oncol"},{"issue":"10","key":"10.1016\/j.ijgc.2026.105601_bib4","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1093\/ajhp\/zxaf011","article-title":"A review of mirvetuximab soravtansine-gynx in folate receptor alpha-expressing platinum-resistant ovarian cancer","volume":"82","author":"Smith","year":"2025","journal-title":"Am J Health Syst Pharm"},{"issue":"11","key":"10.1016\/j.ijgc.2026.105601_bib5","doi-asserted-by":"crossref","first-page":"5222","DOI":"10.3390\/ijms26115222","article-title":"Folate receptor alpha in advanced epithelial ovarian cancer: diagnostic role and therapeutic implications of a clinically validated biomarker","volume":"26","author":"Zannoni","year":"2025","journal-title":"Int J Mol Sci"},{"issue":"16","key":"10.1016\/j.ijgc.2026.105601_bib6","doi-asserted-by":"crossref","first-page":"7687","DOI":"10.3390\/ijms26167687","article-title":"Interobserver agreement in immunohistochemical evaluation of folate receptor alpha (FR\u03b1) in ovarian cancer: a multicentre study","volume":"26","author":"Zannoni","year":"2025","journal-title":"Int J Mol Sci"},{"issue":"13","key":"10.1016\/j.ijgc.2026.105601_bib7","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1200\/JCO.22.01900","article-title":"Efficacy and safety of mirvetuximab soravtansine in patients with platinum-resistant ovarian cancer with high folate receptor alpha expression: results from the SORAYA study","volume":"41","author":"Matulonis","year":"2023","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.ijgc.2026.105601_bib8","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1056\/NEJMoa2309169","article-title":"Mirvetuximab soravtansine in FRalpha-positive, platinum-resistant ovarian cancer","volume":"389","author":"Moore","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijgc.2026.105601_bib9","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1016\/j.ygyno.2024.07.023","article-title":"Patient-reported outcome results from phase III MIRASOL trial of mirvetuximab soravtansine versus investigator\u2019s choice of chemotherapy in FR\u03b1-positive, platinum-resistant ovarian cancer","volume":"190","author":"Konecny","year":"2024","journal-title":"Gynecol Oncol"},{"issue":"4","key":"10.1016\/j.ijgc.2026.105601_bib10","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/S1470-2045(25)00021-X","article-title":"Patient-reported outcomes from the MIRASOL trial evaluating mirvetuximab soravtansine versus chemotherapy in patients with folate receptor alpha-positive, platinum-resistant ovarian cancer: a randomised, open-label, phase 3 trial","volume":"26","author":"Van Gorp","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijgc.2026.105601_bib11","unstructured":"FDA approves mirvetuximab soravtansine-gynx for FR\u03b1 positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer. US Food and Drug Administration. Accessed 16 June 2026. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-mirvetuximab-soravtansine-gynx-fra-positive-platinum-resistant-epithelial-ovarian."},{"issue":"19","key":"10.1016\/j.ijgc.2026.105601_bib12","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.1158\/1078-0432.CCR-23-0991","article-title":"FDA approval summary: mirvetuximab Soravtansine-Gynx for FRalpha-positive, platinum-resistant ovarian cancer","volume":"29","author":"Dilawari","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijgc.2026.105601_bib13","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ygyno.2024.06.008","article-title":"Folate receptor alpha expression in low-grade serous ovarian cancer: exploring new therapeutic possibilities","volume":"188","author":"Manning-Geist","year":"2024","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ijgc.2026.105601_bib14","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ygyno.2024.09.021","article-title":"Characterizing the genomic landscape through the lens of FOLR1 status in low and high grade serous ovarian carcinoma","volume":"191","author":"Rushton","year":"2024","journal-title":"Gynecol Oncol"},{"issue":"13","key":"10.1016\/j.ijgc.2026.105601_bib15","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1002\/cncr.34753","article-title":"Chemotherapy response in low-grade serous ovarian carcinoma at a comprehensive cancer center: readdressing the roles of platinum and cytotoxic therapies","volume":"129","author":"Manning-Geist","year":"2023","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.ijgc.2026.105601_bib16","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ijgc.2026.105601_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbi.2019.103208","article-title":"The REDCap consortium: building an international community of software platform partners","volume":"95","author":"Harris","year":"2019","journal-title":"J Biomed Inform"},{"issue":"2","key":"10.1016\/j.ijgc.2026.105601_bib18","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research Electronic Data Capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J Biomed Inform"},{"issue":"2","key":"10.1016\/j.ijgc.2026.105601_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijgc.2025.102779","article-title":"Folate receptor alpha as a successful biomarker in the treatment of low-grade serous ovarian cancer patients using preclinical and clinical models","volume":"36","author":"Ettorre","year":"2026","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ijgc.2026.105601_bib20","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.ygyno.2023.01.020","article-title":"Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FR\u03b1)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer","volume":"170","author":"Gilbert","year":"2023","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.ijgc.2026.105601_bib21","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.ygyno.2020.01.037","article-title":"Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FR\u03b1)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer","volume":"157","author":"O\u2019Malley","year":"2020","journal-title":"Gynecol Oncol"},{"issue":"suppl 15","key":"10.1016\/j.ijgc.2026.105601_bib22","volume":"34","author":"O\u2019Malley","year":"2016","journal-title":"J Clin Oncol"},{"issue":"suppl 16","key":"10.1016\/j.ijgc.2026.105601_bib23","article-title":"GLORIOSA: a randomized, open-label, phase 3 study of mirvetuximab soravtansine with bevacizumab vs. bevacizumab as maintenance in platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer","volume":"41","author":"O\u2019Malley","year":"2023","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.ijgc.2026.105601_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijgc.2025.102879","article-title":"Improved progression-free survival with mirvetuximab and bevacizumab in platinum-resistant ovarian cancer: a retrospective real-world analysis","volume":"36","author":"Roberts","year":"2026","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ijgc.2026.105601_bib25","doi-asserted-by":"crossref","first-page":"A1","DOI":"10.1016\/j.ygyno.2024.11.008","article-title":"Following the folate receptor: expanding targeted treatment options in low grade serous ovarian carcinoma","volume":"191","author":"Thayer","year":"2024","journal-title":"Gynecol Oncol"},{"issue":"5","key":"10.1016\/j.ijgc.2026.105601_bib26","doi-asserted-by":"crossref","first-page":"e74","DOI":"10.3802\/jgo.2025.36.e74","article-title":"FOLR1 as a therapeutic target in platinum-resistant ovarian carcinoma: unique expression patterns across ovarian carcinoma histotypes and molecular subtypes of low-grade serous carcinoma","volume":"36","author":"Leung","year":"2025","journal-title":"J Gynecol Oncol"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X26011321?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X26011321?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T19:27:34Z","timestamp":1791660454000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X26011321"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":26,"alternative-id":["S1048891X26011321"],"URL":"https:\/\/doi.org\/10.1016\/j.ijgc.2026.105601","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Early experience with mirvetuximab soravtansine in the treatment of recurrent low- grade serous ovarian carcinoma","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijgc.2026.105601","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Society of Gynaecological Oncology and the International Gynecologic Cancer Society. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105601"}}